Lysogene raises $25M in Paris IPO; Chan Zuckerberg Biohub starts handing out $50M
• The gene therapy company Lysogene has raised $25 million from an IPO on Euronext Paris designed to fund its R&D work. “This IPO will enable us to pursue the development of two drugs to treat two polysdisabling, devastating and deadly diseases of the central nervous system, which start in infancy and lead to the patients premature death,” said CEO Karen Aiach. “By focusing directly on the cause, our treatments aim to cure these diseases the medical needs of which are largely unsatisfied and currently uncovered.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.